These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6218370)

  • 21. Treatment of painful bone lesions and hypercalcemia.
    Ascari E; Attardo-Parrinello G; Merlini G
    Eur J Haematol Suppl; 1989; 51():135-9. PubMed ID: 2534078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dichloromethylene diphosphonate in the treatment of lytic bone metastases].
    Chantraine A; Jung A; van Ouwenaller C; Donath A
    Presse Med; 1984 Feb; 13(8):479-82. PubMed ID: 6230629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
    Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
    J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic lymphocytic leukemia and hypercalcemia: treatment with dichloromethylene diphosphonate.
    Siris ES; Grossbard L; Halper JP; Blume RS; Jacobs TP
    Metab Bone Dis Relat Res; 1983-1984; 5(2):61-3. PubMed ID: 6231452
    [No Abstract]   [Full Text] [Related]  

  • 25. Bisphosphonates in multiple myeloma.
    Berenson JR
    Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug treatment of primary hyperparathyroidism: use of clodronate disodium.
    Douglas DL; Kanis JA; Paterson AD; Beard DJ; Cameron EC; Watson ME; Woodhead S; Williams J; Russell RG
    Br Med J (Clin Res Ed); 1983 Feb; 286(6365):587-90. PubMed ID: 6218861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton.
    Adami S; Salvagno G; Guarrera G; Bianchi G; Dorizzi R; Rosini S; Mobilio G; Lo Cascio V
    J Urol; 1985 Dec; 134(6):1152-4. PubMed ID: 2932559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
    Chapuy MC; Charhon SA; Meunier PJ
    Metab Bone Dis Relat Res; 1983; 4(6):325-8. PubMed ID: 6229683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.
    Lahtinen R; Laakso M; Palva I; Virkkunen P; Elomaa I
    Lancet; 1992 Oct; 340(8827):1049-52. PubMed ID: 1357451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP).
    Conte N; Di Virgilio R; Roiter I; Caberlotto L
    Tumori; 1985 Feb; 71(1):51-4. PubMed ID: 3157251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clodronate and myeloma].
    Jantunen E; Lahtinen R; Laakso M
    Duodecim; 1995; 111(12):1085-7. PubMed ID: 9213542
    [No Abstract]   [Full Text] [Related]  

  • 33. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults.
    McCloskey EV; MacLennan IC; Drayson MT; Chapman C; Dunn J; Kanis JA
    Br J Haematol; 1998 Feb; 100(2):317-25. PubMed ID: 9488619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonate therapy in multiple myeloma.
    Laakso M; Jantunen E
    Acta Oncol; 1996; 35 Suppl 5():55-6. PubMed ID: 9142966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of clodronate on immobilization bone loss.
    Minaire P; Depassio J; Berard E; Meunier PJ; Edouard C; Pilonchery G; Goedert G
    Bone; 1987; 8 Suppl 1():S63-8. PubMed ID: 2961357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP).
    Adami S; Guarrera G; Salvagno G; Spiazzi G; Marini G; Rosini S; Lo Cascio V
    Metab Bone Dis Relat Res; 1984; 5(6):265-7. PubMed ID: 6238218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone.
    Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Vignon E; Trechsel U; Mathieu L; Edouard C
    Adv Exp Med Biol; 1980; 128():299-309. PubMed ID: 6448538
    [No Abstract]   [Full Text] [Related]  

  • 38. Clodronate in the medical management of hyperparathyroidism.
    Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
    Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hypercalcemic crises of myelomatous origin. Treatment with dichloromethylene diphosphonate].
    Conte N; Di Virgilio R; Roiter I
    Presse Med; 1984 Nov; 13(42):2586. PubMed ID: 6239268
    [No Abstract]   [Full Text] [Related]  

  • 40. Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.
    Laakso M; Lahtinen R; Virkkunen P; Elomaa I
    Br J Haematol; 1994 Aug; 87(4):725-9. PubMed ID: 7986713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.